{
  "docId": "019de070-182a-72ba-952e-2b048c610e12",
  "docSlug": "cea7bfa85dc209a87c7b2adf6cd4697f",
  "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 22 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Aeglea BioTherapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2020-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 16,
  "pageCount": 22,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "problem_statement",
  "function": "frame_problem",
  "density": "balanced",
  "nDataPoints": 2,
  "notes": "The slide uses a structured table format to define the clinical problem space.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-182a-72ba-952e-2b048c610e12/16",
  "deckHref": "/decks/019de070-182a-72ba-952e-2b048c610e12",
  "deckJsonHref": "/decks/019de070-182a-72ba-952e-2b048c610e12.json",
  "deckAnchorHref": "/decks/019de070-182a-72ba-952e-2b048c610e12#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.031,
        "w": 0.511,
        "x": 0.048,
        "y": 0.135
      },
      "kind": "paragraph",
      "text": "Novel homocysteine/homocystine metabolizing enzyme",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a2075bcf-7756-422c-be29-e327657fcafb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.942,
        "x": 0.029,
        "y": 0.25
      },
      "kind": "table",
      "text": "Unmet Medical Need: Very high - no effective therapy for many patients; Early mortality and serious complications (Lens dislocation, glaucoma, skeletal abnormalities, learning problems, vascular abnormalities). Patient Population: >5,000 patients with B6 non-responsive CBS Deficiency; Additional opportunity in B6 responsive patients (>5,000). Diagnosis: Plasma total homocysteine level/enzyme activity assay and/or mutation analysis; Newborn screening in all U.S. states.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0722fb06-0046-4040-8532-e770d09dd21f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.045,
        "w": 0.431,
        "x": 0.048,
        "y": 0.068
      },
      "kind": "title",
      "text": "ACN00177: Homocystinuria",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "86f7876a-5718-44cc-b182-a90741012ade",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 19,
      "from": 16,
      "name": "Pattern Hunter",
      "slug": "02-pattern-hunter",
      "bestFor": "Time-pressed audiences, building consensus, when data is strong",
      "matchId": "1f636e64-203c-4fd6-a848-023a41807e71",
      "evidence": "Clear presentation of disease and treatment effects",
      "position": 1,
      "objective": "Understanding the problem and solution for Homocystinuria",
      "structure": "Evidence A -> Evidence B -> Evidence C -> Pattern/Conclusion",
      "confidence": 0.7,
      "description": "Group multiple pieces of evidence that together point to a pattern or conclusion"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}